NDAINTRAVENOUSPOWDERPriority Review
Approved
Nov 2022
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
Pharmacologic Class:
Cholecystokinin Analog
Loss of Exclusivity
LOE Date
Apr 20, 2038
147 months away
Patent Expiry
Apr 20, 2038
Cholecystokinin Analog